Background: While Parkinson disease (PD) is consistently associated with impaired olfaction, one study reported better olfaction among Parkin mutation carriers than noncarriers. Whether olfaction differs between Parkin mutation heterozygotes and carriers of 2 Parkin mutations (compound heterozygotes) is unknown.
patients with PD. 22, 23 Four of these carriers of Parkin mutations were heterozygotes (Dr. N. Khan, personal communication) . Olfactory performance in Parkin mutation heterozygotes vs compound heterozygotes has never been reported. The purpose of this study was to compare olfactory function among carriers of a single Parkin mutation, carriers of 2 Parkin mutations, and noncarriers with and without PD.
METHODS Participants. This study included 44 individuals with EOPD (probands) who participated in Part II of the Consortium on Risk for Early-Onset Parkinson Disease study (CORE-PD), and 80 of their family members. The details of the CORE-PD study are described elsewhere. 24 In brief, patients with PD were recruited from 13 sites based on age at onset (AAO) of PD Յ50 years and performance on the Mini-Mental State Examination (MMSE) 25 Ͼ23 to ensure that a reliable history could be obtained from each subject. A blood sample for DNA was sent to the NINDS Human Genetics Resource Center DNA and Cell Line Repository (http://ccr.coriell.org). In part II of CORE-PD, patients who carried Parkin mutations and a sample of those who did not carry Parkin mutations, as well as their family members, underwent a detailed neurologic, neuropsychological, and psychiatric assessment. Beginning in 2007, olfactory function was measured by the University of Pennsylvania Smell Identification Test (UPSIT, 26 Sensonics, Inc., Haddonfield, NJ). The UPSIT consists of 40 standardized encapsulated odors. Raw scores are calculated as the simple number of correct identifications ranging from 0 to 40; higher scores indicate better olfaction. Anosmia is defined as a score of 18 or lower and severe microsmia is defined as a score of 19 -25 in people above age 15. 27 The reliability of UPSIT is well-established. 26 The UPSIT was obtained only if participants denied any upper respiratory illness, as suggested by the UPSIT manual. Smoking history was obtained on all participants. All examiners were unaware of the genetic status of the participants at the time of recruitment and thereafter.
Probands and family members were screened for Parkin mutations, as well as for common mutations in LRRK2 and glucocere- brosidase (GBA), using previously described methods, 24 after the examination was complete. In addition, most participants, including 31 of the 43 probands with PD and all family members, were screened for mutations in ␣-synuclein (SNCA; A157T, A88P, and E136K), DJ-1 (L166P, M26I, D149A, and A104T), and PTENinduced putative kinase 1 (PINK-1; W437X and G309D). 28 None were aware of their mutation status. Carriers of LRRK2 or GBA were excluded from the analyses. No carriers of mutations in SNCA, DJ-1, or PINK-1 were detected.
Standard protocol approvals, registrations, and patient consents. Institutional review boards at all participating sites approved the protocols and consent procedures. Written informed consent was obtained from all participants in the study.
Data analysis. Probands. Demographics, clinical characteristics, and UPSIT performance were compared among the 3 groups defined by Parkin genotype using univariate analysis of variance and 2 tests as appropriate. A linear regression model was constructed to assess the association between UPSIT score (outcome) and mutation status (predictor), adjusting for age, gender, disease duration, and history of smoking (past and current vs never). Finally, we compared the proportion of probands with severe olfactory impairment (either severe microsmia or anosmia), defined as a score of 25 or lower (UPSIT manual) 27 among the genetic groups. Unaffected family members. Given that only 2 family members without PD carried 2 Parkin mutations (both compound heterozygotes), we restricted the analysis of UPSIT performance in family members to Parkin mutation heterozygotes and noncarriers. We used generalized estimating equations (GEE) to adjust for familial clustering, age, gender, and history of smoking. Finally, we compared UPSIT performance between Parkin mutation heterozygotes with and without PD using the GEE model, to assess whether hyposmia was associated with PD among mutation carriers.
RESULTS Probands with PD. Probands with PD included 9 carriers of 2 Parkin mutations (all compound heterozygotes), 10 Parkin mutation heterozygotes, and 25 noncarriers. The specific mutations in Parkin carriers are described in table 1. All the Parkin mutations reported are considered pathogenic. 24 Seven of the 9 carriers of 2 Parkin mutations had sufficient family data to conclude that the 2 Parkin mutations are on 2 different alleles (table 1) .
Probands with PD who carried 2 Parkin mutations performed significantly better on the UPSIT (31.9) than probands who were heterozygotes (20.1) or noncarriers (19.9), despite longer disease duration (figure 1, table 2). Mean UPSIT performance of probands who were Parkin mutation heterozygotes was within the range of severe microsmia (19 -25) , and was not significantly different from probands who were noncarriers. In a linear regression model including all probands with PD, carrying 2 Parkin mutations was associated with higher UPSIT scores when compared to Parkin mutation heterozygotes (10.9point difference, p ϭ 0.005) or to noncarriers (10.7point difference, p ϭ 0.003), after adjustment for gender, age, disease duration, and history of smoking. We did not find any association between olfaction and Parkin mutation type (point mutations vs gene dosage alterations), or with disease severity indi- 
cators, including Unified Parkinson's Disease Rating
Scale-III and disease duration. The proportion of Parkin mutation heterozygote and noncarrier probands who were either severely microsmic or anos-mic combined (i.e., UPSIT score lower than 26) was higher than Parkin compound heterozygotes ( p ϭ 0.02, figure 2 ). The significant difference between Parkin mutation heterozygotes and compound heterozygotes did not change after excluding the 2 compound heterozygotes on whom there were insufficient family data to confirm compound heterozygocity status.
Family members without PD. Family members included 80 individuals from 37 families: 60 noncarriers, 18 Parkin mutation heterozygotes, and 2 compound heterozygotes. The specific mutations in family members who were Parkin carriers are described in Among individuals who were heterozygous carriers of Parkin mutations (probands with PD and relatives without PD), performance on the UPSIT was better in relatives without PD than in probands with EOPD (32.5 vs 20.1, p ϭ 0.001, adjusted for familial clustering, age, gender, and history of smoking in a GEE model); however, in 12% (2/17) of the heterozygote family members without PD (from 2 different families) UPSIT performance was consistent with severe microsmia or anosmia. Both carried deletions in the Parkin gene (table 3) . Both Parkin compound heterozygotes without PD had normal smell performance (table 3) ; however, statistical analysis was not performed given the small number (n ϭ 2). DISCUSSION Impairment in olfactory function is an early finding in idiopathic PD, and is not associated with severity of motor function or medication dosage. 29, 30 Our study of olfaction in a genotyped sample of EOPD confirms previous reports of better olfaction in carriers of 2 Parkin mutations with PD, 22, 23 and demonstrates impaired olfaction in Parkin mutation heterozygotes with PD, similar to that of people with PD who were Parkin noncarriers and significantly worse than compound heterozygotes with PD. The role of Parkin mutation heterozygosity in the pathogenesis of PD is controversial. [14] [15] [16] [17] Data supporting the hypothesis that heterozygous mutations convey a risk for PD include imaging findings [18] [19] [20] and studies showing an increased frequency of heterozygous carriers in PD cases compared to controls. 15 Our finding of similar olfactory performance in Parkin heterozygotes with PD and noncarriers with PD may be viewed as consistent with the hypothesis that Parkin mutation heterozygosity is not an independent risk factor for PD. Alternatively, poor performance on the UPSIT may reflect a different distribution of pathology among Parkin mutation heterozygotes compared to compound heterozygotes.
Olfactory impairment in PD is associated with Lewy body infiltration of the olfactory bulb and tract. 31 Neuropathologic staging of PD suggests the presence of Lewy bodies in the olfactory bulb in Braak stages 1-2, even before the disease reaches the substantia nigra (stage 3). 32 To our knowledge, 7 autopsies of individuals with Parkin mutations have been reported. Only 2 of the 6 homozygotes/compound heterozygotes had Lewy bodies, 33, 34 whereas the clinical course and pathology from a single autopsy of a Parkin mutation heterozygote was consistent with progressive supranuclear palsy. 35 Based on our findings of different olfactory performance in Parkin mutation heterozygotes and Parkin compound heterozygotes, we hypothesize that better UPSIT performance is inversely correlated with Lewy body pathology, and that Par-kin heterozygotes with PD have Lewy bodies in the olfactory bulb; however, autopsy data are lacking, and further research is required to address the relationship between olfactory performance and the underlying disease mechanism.
Limitations of our study include its sample size, which did not allow us to analyze point mutation carriers and gene dosage alterations carriers in the Parkin gene separately. While we excluded carriers of common mutations in LRRK2 and GBA to avoid confounders, we only screened for specific mutations and did not sequence the ␣-synuclein DJ-1 or PINK-1 genes, which are associated with impaired olfaction. 36 When Parkin mutation heterozygotes with and without PD were compared, olfactory impairment was associated with PD, supporting the notion that hyposmia in Parkin mutation heterozygotes is related to PD rather than to Parkin genotype. However, we also noted that 2 (12%) of the Parkin mutation heterozygotes without PD manifested impaired olfaction. In light of 2 prospective studies that demonstrated that 10%-13% of individuals who had both hyposmia and abnormal functional imaging at baseline developed PD over a 2-to 5-year period, 37,38 a longitudinal follow-up of these carriers is warranted to determine whether hyposmia can be used as an early marker of PD in Parkin heterozygous mutation carriers, and whether Parkin mutation heterozygosity is indeed a risk factor for PD. 
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